Key result
Post-DIHS giant cell myocarditis carries ~82% mortality, frequently emerging during steroid tapering.
Why the study?
Giant cell myocarditis is a fatal disease that requires mechanical circulatory support for cardiac standstill, and some cases are reportedly associated with drug-induced hypersensitivity syndrome.
Case Report (n=11)
Giant cell myocarditis is a rare, highly fatal potential complication of drug-induced hypersensitivity syndrome that frequently presents during steroid tapering and often requires aggressive mechanical circulatory support.
Answers are grounded in this paper and cite their sources.
Requires vigilance for myocarditis during steroid tapering after drug-induced hypersensitivity syndrome; leaves optimal management open given Level 5 evidence.
Giant cell myocarditis (GCM) is a rare but fatal disease that can lead to cardiac failure. Survival with a cardiac standstill requires mechanical circulatory support or a biventricular assist device (BiVAD) and prolonged survival is extremely rare. Drug-induced hypersensitivity syndrome (DIHS) is a severe cutaneous adverse reaction. Some cases of DIHS are reportedly associated with the onset of GCM. We present a case of a 28-year-old woman who developed GCM during steroid tapering after DIHS. She went into continuous cardiac standstill but survived for 74 days under BiVAD support. Our case is noteworthy because the histopathologic specimens obtained on three occasions contributed to the diagnosis of this particular condition over time. We also reviewed previous literature on concomitant cases of GCM and DIHS. We found that two are potentially associated and most cases of GCM occur within 3 months of DIHS during steroid tapering.
No takes yet. Share an insight, caveat, or question.
Ono et al. (2024) conducted a case report in Giant cell myocarditis with drug-induced hypersensitivity syndrome (n=11). Drug-induced hypersensitivity syndrome and steroid tapering was evaluated on Overall mortality. Giant cell myocarditis can develop within 3 months of drug-induced hypersensitivity syndrome during steroid tapering, with an overall mortality rate of 81.8%.
Synapse has enriched 10 related papers. Consider them for comparative context: